Literature DB >> 24387753

An update on the pharmacotherapy options for pediatric diabetes.

M Loredana Marcovecchio1, Francesco Chiarelli.   

Abstract

INTRODUCTION: Diabetes mellitus is a frequent endocrine disease during childhood and adolescence. Achieving a good glycemic control is of paramount importance to avoid short- and long-term complications and to allow a normal growth and quality of life. AREAS COVERED: This review offers an update on current available treatment strategies for type 1 and type 2 diabetes approved for use in children and adolescents. EXPERT OPINION: Although many progresses have been made in the field of diabetes management in children and adolescents, there are still several problems to deal with. With regard to type 1 diabetes, insulin remains the main and essential therapeutic strategy. However, the main issue is to develop a system that allows more physiological insulin coverage and reduces the risk of hypoglycemia and weight gain. Adjunct therapies would be invaluable for patients struggling to achieve an acceptable glycemic control. Treatment of type 2 diabetes is based on lifestyle interventions and metformin is the first-line drug for children older than 10 years. As for type 1 diabetes, there is a strong need for developing new drugs to be used alone or in combination.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24387753     DOI: 10.1517/14712598.2014.874413

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  3 in total

1.  Long term trends in oral antidiabetic drug use among children and adolescents in the Netherlands.

Authors:  S Fazeli Farsani; P C Souverein; J A Overbeek; M M J van der Vorst; C A J Knibbe; R M C Herings; A de Boer; A K Mantel-Teeuwisse
Journal:  Br J Clin Pharmacol       Date:  2015-05-20       Impact factor: 4.335

2.  Pediatric diabetes: Potential for insulin degludec.

Authors:  Sanjay Kalra; Ambika Gopalakrishnan Unnikrishnan; Rakesh Sahay
Journal:  Indian J Endocrinol Metab       Date:  2014-11

Review 3.  Netrin as a Novel Biomarker and Its Therapeutic Implications in Diabetes Mellitus and Diabetes-Associated Complications.

Authors:  Ebrahim M Yimer; Kaleab Alemayehu Zewdie; Hailemichael Zeru Hishe
Journal:  J Diabetes Res       Date:  2018-09-18       Impact factor: 4.011

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.